Integrated alcohol-use and liver care for people with alcohol-associated liver disease
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical Center
This project aims to find out whether combining medicines for alcohol use, counseling, and liver-specialist care helps people with severe alcohol-associated hepatitis live longer and avoid returning to drinking.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11195118 on NIH RePORTER |
What this research studies
You would be cared for by a coordinated team of addiction specialists and liver doctors who deliver combined treatments. Care may include FDA-approved medicines for alcohol use disorder such as acamprosate, behavioral counseling like motivational interviewing, standard liver treatments (for example prednisone where used), and in some cases newer experimental drugs such as IL-22. The work builds on prior trials that showed unexpectedly high short-term survival with prednisone in severe alcohol-associated hepatitis and seeks to confirm those findings while testing integrated care approaches. The study would track survival, return to drinking, and safety outcomes.
Who could benefit from this research
Good fit: Ideal candidates are adults with alcohol-associated liver disease—especially those with severe alcohol-associated hepatitis—who are willing to receive coordinated addiction and liver care and possible medication treatments.
Not a fit: People without alcohol-associated liver disease, those with only mild disease where study therapies are not appropriate, or those unwilling or unable to engage in counseling or study medications may not receive benefit.
Why it matters
Potential benefit: If successful, this approach could lower deaths and reduce relapse by treating alcohol use disorder and liver disease together.
How similar studies have performed: Previous work such as the AlcHepNet trial showed unexpectedly high 90-day survival with prednisone in severe alcohol-associated hepatitis, but those findings need confirmation and testing newer treatments like IL-22 is novel.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Dasarathy, Srinivasan — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Dasarathy, Srinivasan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.